GlassScriptPhysician profile
Melanie Beth Schatz
NPI 1104844372
$2,215.96
in general payments reported to CMS, 2019-2025
30 companies · $475 in 2025
The $475 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $193 · 2021: $34.30 · 2022: $388 · 2023: $347 · 2024: $571 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $372.54 | 2023-2025 | Veozah |
| Caldera Medical, INC | $293.95 | 2024 | Desara |
| Abbvie INC. | $235.08 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $180.92 | 2023-2025 | |
| Coopersurgical, INC. | $142.02 | 2020-2025 | Paragard T 380a |
| Allergan, INC. | $94.85 | 2019-2020 | |
| Exeltis, USA INC. | $93.30 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $68.14 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Amag Pharmaceuticals, INC. | $54.54 | 2019-2020 | |
| Therapeuticsmd, INC. | $53.59 | 2020-2022 | |
| Baxter Healthcare | $52.58 | 2023 | Tisseel |
| Pfizer INC. | $49.85 | 2022-2023 | |
| Meditrina | $42.58 | 2022 | |
| Covidien LP | $42.58 | 2020 | |
| Myovant Sciences INC. | $42.34 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.02 | 2023 | Balcoltra |
| Agile Therapeutics, INC. | $41.09 | 2022-2023 | Twirla |
| Sumitomo Pharma America, INC. | $40.44 | 2023-2025 | Myfembree |
| Amgen INC. | $32.54 | 2020 | |
| Organon LLC | $31.58 | 2022 | |
| Millicent US INC | $31.43 | 2021-2025 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $29.78 | 2023-2024 | Gardasil 9, Gardasil |
| Dysis Medical, INC. | $27.21 | 2019 | |
| Daiichi Sankyo INC. | $21.18 | 2025 | Injectafer |
| Evofem Biosciences, INC. | $19.79 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.52 | 2022 | |
| Sage Therapeutics, LLC | $19.04 | 2025 | Zurzuvae |
| Duchesnay USA Incorporated | $16.73 | 2019 | |
| Smith+Nephew, INC. | $13.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Schatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.